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Background: Upon stimulation with different cytokines, macrophages can undergo classical or alternative
activation to become M1 or M2 macrophages. Alternatively activated (or M2) macrophages are defined by their
expression of specific gene products and play an important role in containing inflammation, removing apoptotic
cells and repairing tissue damage. Whereas it is well-established that IL-4 can drive alternative activation, if lack of
TGFβ signaling at physiological levels affects M2 polarization has not been addressed.
Results: Vav1-Cre x TβRIIfx/fx mice, lacking TβRII function in hematopoietic cells, exhibited uncontrolled pulmonary
inflammation and developed a lethal autoimmune syndrome at young age. This was accompanied by significantly
increased numbers of splenic neutrophils and T cells as well as elevated hepatic macrophage infiltration and bone
marrow monocyte counts. TβRII-/- CD4+ and CD8+ T-cells in the lymph nodes and spleen expressed increased cell
surface CD44, and CD69 was also higher on CD4+ lymph node T-cells. Loss of TβRII in bone marrow-derived
macrophages (BMDMs) did not affect the ability of these cells to perform efferocytosis. However, these cells were
defective in basal and IL-4-induced arg1 mRNA and Arginase-1 protein production. Moreover, the transcription of
genes that are typically upregulated in M2-polarized macrophages, such as ym1, mcr2 and mgl2, was also decreased
in peritoneal macrophages and IL-4-stimulated TβRII-/- BMDMs. We found that cell surface and mRNA expression of
Galectin-3, which also regulates M2 macrophage polarization, was lower in TβRII-/- BMDMs. Very interestingly, the
impaired ability of these null mutant BMDMs to differentiate into IL-4 polarized macrophages was Stat6- and
Smad3-independent, but correlated with reduced levels of phospho-Akt and β-catenin.
Conclusions: Our results establish a novel biological role for TGFβ signaling in controlling expression of genes
characteristic for alternatively activated macrophages. We speculate that lack of TβRII signaling reduces the
anti-inflammatory M2 phenotype of macrophages because of reduced expression of these products. This
would cause defects in the ability of the M2 macrophages to negatively regulate other immune cells such as
T-cells in the lung, possibly explaining the systemic inflammation observed in Vav1-Cre x TβRIIfx/fx mice.
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Transforming growth factor beta (TGFβ) is a multi-
functional cytokine that regulates cell proliferation, dif-
ferentiation, migration and survival. It plays a critical
role in development, wound healing and immune
responses through its regulatory effects on many cell
types including epithelial and hematopoietic cells [1].
Three isoforms (TGFβ1, β2 and β3), which are encoded* Correspondence: heisterk@hsc.usc.edu
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reproduction in any medium, provided the orby different genes and share high homology, have been
identified in mammals. TGF-β1 is the predominant iso-
form expressed in immune cells, but all three isoforms
have similar properties in vitro. However, in vivo, they
have both redundant and distinctive functions because
of spatial and temporal expression during development
[2-4]. TGFβ signals are transmitted via a cell surface re-
ceptor complex consisting of the TGFβ type I receptor
(TβRI) and TGFβ type II receptor (TβRII). To initiate
signal transduction, TGFβ binds to TβRII, which in turn
recruits TβRI, leading to the formation of a tetrameric
receptor complex. The constitutively active serine/td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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activates Smad2 and Smad3 via phosphorylation. Acti-
vated Smad2/3 binds Smad4. Subsequently, the Smad2/
3/4 complex translocates to nucleus to regulate gene ex-
pression [5]. Besides the Smad-dependent pathways,
TGFβ also activates the Erk [6], PI3K [7], p38 and JNK
[8] pathways, each of which results in a unique pattern
of gene expression and thus physiological function.
The importance of TGFβ signaling in the immune sys-
tem is highlighted by the finding that mice lacking
TGFβ1 develop a severe lethal wasting syndrome within
3 weeks of birth, associated with a mixed inflammatory
cell infiltration and lesions in different organs including
the heart and lungs [9,10]. Since TβRII is the primary re-
ceptor for TGFβ, Leveen et al. [11] generated a condi-
tional ablation model for TGFβ signaling using TβRIIfx/fx
x Mx1-Cre mice. Upon deletion of the TβRII in the bone
marrow of adult mice, a lethal inflammatory disorder
that is similar to the phenotype of the TGFβ1-null
mutants was observed. Such lethal disorder was transfer-
able through bone marrow transplantation, indicating
that a deficiency of TGFβ signaling in cells of bone mar-
row origin is sufficient to cause a lethal inflammatory
disease [11]. Further studies on TGFβ1-null mutants or
mice with bone marrow-specific deletion of TβRII
showed, that TGFβ signaling is critical for T-cell im-
munity [12-14], whereas possible functional defects of
macrophages lacking TGFβ signaling were largely
overlooked.
Macrophages are important immune cells that have di-
verse biological functions, which are, to a large extent,
determined by their activation states. Exposure to LPS
and IFNγ induces macrophages to undergo classical acti-
vation and differentiate into M1 macrophages. M1
macrophages are characterized by the production of
pro-inflammatory cytokines (TNFα and IL-6) and the in-
duction of iNOS (NOS2), which is essential for generat-
ing reactive oxygen species such as NO [15,16]. Because
of their pro-inflammatory and cytotoxic activities, M1
macrophages play a critical role in elimination of patho-
gens and initiation of inflammation. In contrast, when
macrophages are exposed to IL-4 (or IL-13), they
undergo alternative activation and polarize into M2
macrophages, which are anti-inflammatory. M2 macro-
phages produce anti-inflammatory cytokines (IL-10) and
have increased expression of Arginase-1, which com-
petes with iNOS for a common limiting substrate L-
arginine [17]. M2 macrophages are primarily involved in
phagocytosis of apoptotic cells, resolution of inflamma-
tion, tissue repair, and wound healing [18-21].
Although TGFβ plays a critical role in T-cell immun-
ity, surprisingly, few studies have evaluated the effect of
TGFβ signaling on macrophages. To begin to answer
this question, we generated mice lacking TβRII and thusTGFβ signaling in hematopoietic cells using TβRIIfx/fx and
Vav1-Cre mice. Vav1-Cre has been shown to direct Cre-
mediated recombination in cells of the hematopoietic
lineage [22]. Interestingly, our studies reveal that macro-
phages lacking TβRII have defects in expression of a set of
genes that form the hallmark of the M2 polarizing pro-
gram, suggesting that TGFβ signaling is needed for the al-
ternative activation of macrophages.
Results
Mice lacking TβRII in hematopoietic cells develop a lethal
inflammatory and autoimmune syndrome
Vav1 is a hematopoietic-specific activator for Rac
GTPases, and the Vav1 promoter has been widely used
to direct expression of genes selectively in the
hematopoietic lineage [22]. Thus, in Vav1-Cre x TβRIIfx/fx
(TβRII-/-) mice, the Vav1-Cre transgene only ablates TβRII
in hematopoietic cells. We found that mice lacking
TβRII function in such cell types were ~50% lighter
than wild type (WT) littermates (Figure 1A) and usu-
ally died at the age of 24-28 days. These TβRII-/- mice
showed classical hallmarks of acute lung inflamma-
tion. Total cell numbers in the BALF of TβRII-/- mice
were significantly higher than those of WT mice
(Figure 1B). Whereas BALF cell populations of age-
matched WT mice consisted, as expected, almost en-
tirely of alveolar macrophages, those of TβRII-/- mice
instead contained many neutrophils, lymphocytes and
monocytes (Figure 1 C and D).
Mice lacking TβRII in hematopoietic cells exhibited a
normal-sized thymus but enlarged lymph nodes and
spleen (Figure 1E), which correlated with a greatly
increased cellularity of these tissues (Figure 1 F and G).
TβRII-/- spleens contained increased total neutrophil and
T-cell numbers, while total monocyte and B-cell num-
bers were comparable between genotypes (Figure 1H-K).
Strikingly, monocyte numbers in bone marrow, and
macrophage infiltration in liver were significantly
increased in TβRII-/- mice (Figure 1 L and M). Since
macrophage infiltration in liver is a sign of autoimmune
disease, the increased infiltration of macrophages in the
livers of TβRII-/- mice is consistent with the observed in-
flammatory autoimmune syndrome. We next examined
spleen, lymph nodes and thymus for the major T-cell
subsets using FACS. Analysis of the thymus showed WT
and TβRII-/- mice had a similar distribution of CD4+,
CD8+ and double positive (DP) or double negative (DN)
subsets (Additional file 1: Figure S1 A and B). This indi-
cates there were no abnormalities in T-cell development,
which is consistent with a previous report that TGFβ sig-
naling is not required for thymocyte differentiation [12].
We also found that CD25 expression on CD4+ T cells was
comparable in thymus, spleen and lymph nodes of WT
and TβRII-/- mice (Additional file 1: Figure S1C),
Figure 1 Mice lacking TβRII in hematopoietic cells develop a lethal inflammatory and autoimmune syndrome. (A) Body weight of male
and female Vav-Cre x TβRIIfx/fx (TβRII-/-) mice and littermate controls at postnatal day 18-21. (B) Total cell counts and (C) differential cell counts in
BALF of WT and TβRII-/- mice at postnatal day 18-21. Solid bar, WT; Open bar, TβRII-/- samples. Differences are significant (p< 0.01) for all cell
populations in panel C. (D) Wright-Giemsa-stained BALF cells from the indicated genotypes (18-day old littermates). Note the presence of a single
cell type - the alveolar macrophage - in the control lung, whereas the TβRII-/- sample contains neutrophils, monocytes and lymphocytes. (E)
Photographic images of spleens and lymph nodes; total cell counts in (F) spleens and (G) lymph nodes; total numbers of (H) monocytes, (I)
neutrophils, (J) T-cells and (K) B-cells in spleen; total counts of bone marrow monocytes (L) and liver macrophages (M) in WT (filled circles)and
TβRII-/- (KO, open circles) mice (n = 3, **p< 0.01; ***p< 0.001).
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ment of Treg cells and consistent with previous studies
[23,24].
Analysis of the spleen and lymph nodes showed simi-
lar percentages of CD4+ and CD8+ T-cells, although
their absolute numbers were increased in TβRII-/- mice(not shown). Interestingly, however, there was a dra-
matic increase in expression of CD44 on T-cells. Around
20% of splenic CD4+ T-cells and 40% of CD8+ T-cells
expressed CD44 in WT mice, while 90-95% of T-cells
lacking TβRII had CD44 expression. This was also found
in lymph nodes (Additional file 1: Figure S1 E and F). In
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cells in lymph nodes of TβRII-/- mice expressed CD69
(Additional file: 1 Figure S1G). Since CD44 and CD69
are T cell activation markers, our data indicate that one
physiological role of TβRII signaling is to suppress T cell
activation.
Expression of M2 markers on BMDMs is impaired in the
absence of TβRII signaling
The lack of normal alveolar macrophages in the BALF of
TβRII-/- mice could be associated with intrinsic defects
in those macrophages, or could be caused by the envir-
onment, since it is well-known that monocytes from the
blood can differentiate into different types of macro-
phages depending upon environmental factors. Treat-
ment with LPS and IFNγ will generate classically
activated M1 macrophages, whereas treatment with IL-4
and dexamethasone generates M2a and M2c polarized
macrophages, respectively. To examine macrophages
lacking TβRII without the presence of other, possibly
confounding, cell types, we isolated bone marrow-
derived macrophage/monocytes (BMDMs) from the
TβRII-/- mice.
FACS analysis of WT and TβRII-/- BMDMs after 11 days
in culture with M-CSF, a macrophage growth factor,
showed that cells of both genotypes were uniformly
Ly6GlowCD11bhi and expressed F4/80, a pan-macrophage
surface marker (Additional file 1: Figure S2A), indicating
that the purity of the isolated BMDMs is very high
(~99%). We then treated these BMDMs with stimuli that
are typically used to generate different subsets of polarized
macrophages. Additional file 1: Figure S2B illustrates that,
as reported previously [15,20,25], these stimuli generate
morphologically distinct populations. However, BMDMs
with or without TβRII were morphologically similar. We
also investigated the efficiency of Vav1-Cre-mediated abla-
tion of the TGFβRII in these cells. Quantitative real-time
PCR on DNA from BMDMs showed that, although the
deletion was efficient, there was a residual signal of about
6% for TβRII present in Vav1-Cre xTβRIIfx/fx BMDMs
(Additional file 1: Figure S2E).
We next assayed WT and TβRII-/- BMDM for their
ability to phagocytose apoptotic cells. As shown in
Additional file 1: Figure S2C, there were no significant
differences in the ability of M0 BMDMs with or with-
out TβRII to perform efferocytosis. Next, we polarized
them using different agents including LPS/IFNγ (M1),
IL-4 (M2) and hTGFβ1. BMDMs polarized towards the
M1 phenotype had significantly decreased ability to
phagocytose dying cells (Additional file 1: Figure S2D),
but no significant differences were observed between
WT and TβRII-/- BMDMs. We also tested migration.
In contrast to bone-marrow derived neutrophils, which
showed significant migration towards 0.1 ng/mlTGFβ1, bone marrow-derived macrophages did not
migrate towards 5 ng/ml TGFβ1 (not shown).
A classical readout for macrophage polarization states
is the induction of either iNOS (M1) or Arginase-1
(M2), two enzymes that compete for the common sub-
strate L-arginine. As illustrated in Figure 2A, iNOS was
not expressed in M0 or M2 macrophages. Lack of TβRII
allowed the normal production of iNOS upon stimula-
tion with LPS/IFNγ. As reported previously [26], there
was a baseline level of Arginase-1 (Arg-1) expression in
non-polarized macrophages, which was enhanced by
treatment with LPS. Remarkably, TβRII-/- BMDMs had
very low baseline levels of Arg-1, showed severely
impaired induction of Arg-1 by LPS and had profoundly
reduced induction of Arg-1 by IL-4 treatment. Similar
defects in Arg-1 expression were obtained when M1-
polarized (LPS/IFNγ-treated) TβRII-/- macrophages were
subsequently treated with IL-4 to re-polarize them to an
M2 phenotype. Interestingly, macrophages lacking
Smad3 had normal induction of Arg-1, indicating that
the mechanism is Smad3-independent (Additional file 1:
Figure S3).
TGFβ1 is generally regarded as an anti-inflammatory
cytokine and it is frequently listed in the same category
as IL-10 and glucocorticoids such as dexamethasone to
generate M2c-polarized macrophages. However, we
found that WT BMDMs reacted to hTGFβ1 stimulation
with an increased expression of Arg-1 (Figure 2A), simi-
lar to the classical M2a stimulus IL-4, whereas dexa-
methasone (M2c) failed to induce Arg1 (not shown).
To examine if TβRII signaling only regulates Arg-1 ex-
pression, or that there are defects in the expression of
other M2 markers, we next performed real-time RT-
PCR for a number of molecules that are typically up-
regulated in IL-4-polarized macrophages such as ym1,
mrc2 and mgl1/2 [27-30]. As shown in Figure 2B, lack of
TβRII was associated with decreased basal and IL-4-
induced transcription of arg1 and correlated with
decreased transcription of mcr2, mgl2, and ym1, which
are also induced by IL-4. The transcription of mgl1 was
not affected. A similar pattern of reduced basal levels of
M2 markers was also observed in naïve peritoneal
macrophages (Figure 2C). Collectively, our data indicate
that TβRII signaling is critical for the optimal expression
of genes characteristic for M2 polarization.
Lack of TβRII signaling is correlated with decreased
galectin-3, β-catenin and phospho-Akt levels
The molecular pathways that underlie macrophage
polarization are of intense interest due to the impor-
tance of this cell type in a wide array of pathologies,
ranging from autoimmune disorders to cancer, and the
desire to be able to modulate their polarization state.
However, there are very few reports of null mutants in
Figure 2 Expression of M2 markers on BMDMs is impaired in the absence of TβRII signaling. (A) Western blot analysis of WT and TβRII-/-
BMDMs cultured for 24 hrs with medium alone (M0), with LPS/IFNγ (M1), IL-4 (M2), or hTGFβ1. β-actin serves as a loading control. Increased Arg-1
in KO BMDM upon hTGFβ1stimulation due to residual WT cells, see Additional file 1: Figure S2E. (B) Real-time RT-PCR for the indicated genes after
incubation for 24 hrs with medium alone (M0) or IL-4 (M2). (C) Real-time RT-PCR for the indicated genes in naïve peritoneal macrophages. Fold
change is with respect to the expression level of M0 WT. Solid bar, WT; Open bar, TβRII-/- peritoneal macrophages. The results shown are
representative of one of two independently derived sets of BMDMs from different mice.
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reported. One of these is Galectin-3 (lgals3). Macro-
phages lacking Galectin-3 show impaired IL-4-
stimulated M2 polarization and lgals3 null mutants have
reduced TGFβ-associated liver fibrosis [31,32].
We therefore performed real-time RT-PCR for lgals3.
Interestingly, TβRII-/- BMDMs stimulated with IL-4 had
reduced mRNA levels of lgals3 (Figure 3A). To examine
this in more detail, we stimulated WT and TβRII-/-
BMDMs with different polarizing agents and measured
cell surface Galectin-3 expression using FACS. Whereas
the expression of cell surface CD11b was comparable in
these different treatment conditions (not shown),
BMDMs lacking TβRII showed clearly decreasedGalectin-3 expression, especially when exposed to LPS/
IFNγ (Figure 3B).
The E-cadherin/β-catenin complex was recently shown
to be a selective marker for alternatively activated
macrophages [33]. Interestingly, when WT and TβRII-/-
BMDMs were stimulated by IL-4, β-catenin levels were
~35% lower in TβRII-/- than in WT BMDMs
(Figure 3C), further indicating that TβRII signaling pro-
motes M2 macrophage polarization.
To explore the mechanism by which TGFβ contributes
to IL-4-induced M2 polarization, we examined the
downstream targets of IL-4. STAT6 phophorylation is a
key signaling event downstream of the IL-4 receptor
complex, and Akt also becomes activated in this pathway
Figure 3 Lack of TβRII signaling is correlated with decreased Galectin-3, β-catenin and phospho-Akt levels. (A) Real-time RT-PCR for lgals3
in BMDMs. Fold change is with respect to the expression of M0 WT. Solid bar, WT; Open bar, TβRII-/-. (B) Cell surface expression of Galectin-3 on
WT and TβRII-/- BMDMs measured using FACS. MFI, mean fluorescent intensity. The result shown is representative of one of two independently
derived sets of BMDMs from different mice for both A and B. (C) Western blot analysis of β-catenin expression. BMDM were treated with medium
alone (M0), LPS/IFNγ (M1), or IL-4 (M2). Results are representative of 3 pairs of matched WT and TβRII-/- mice. Western blot analysis of
phosphorylated-Stat6 (D) and phosphorylated-Akt (E) in WT and TβRII-/- BMDMs that had been treated with IL-4 for 1 hr. Results are shown for 2
independent mice per genotype. The numbers at the bottom represent the band intensity ratio of phosphorylated protein versus total protein,
normalized to lane 1 on each blot.
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also involved in the IL-4 stimulated polarization that is
co-regulated by TGFβ signaling. As shown in Figure 3D,
p-Stat6 levels were comparable in WT and TβRII-/-
BMDMs stimulated with IL-4. However, p-Akt was
decreased ~50% in the absence of TGFβ signaling
(Figure 3E). This indicates that TGFβ contributes to IL-
4-induced M2 polarization through co-signaling to Akt,
which is one of the TGFβ1 non-Smad-associated signal
transduction pathways reported in other cell types
[37,38].
Discussion
In the current study, we found that the phenotype of mice
born without TβRII function in hematopoietic cells over-
laps with that of mice born without systemic TGFβ1 pro-
duction. In both cases, the null mutants develop a severe
wasting syndrome at around the same time, at 3 weeks of
age [9,10]. However, our mice exhibited splenomegaly and
lymph node enlargement with a corresponding largeincrease in cellularity, whereas Shull et al. reported
reduced size of spleen and Peyer’s patches [10].
We measured dramatically increased expression (15-40%
in WT, 80-95% in KO) of the activation marker CD44, a re-
ceptor for the extracellular matrix (ECM) protein hyalur-
onic acid, on both CD4+ and CD8+ T cells in the spleen
and lymph nodes. Similarly increased CD44 expression was
also observed in mice transplanted with bone marrow of
mice transgenic for a dominant negative TβRII construct
[39]. CD69 is a C-type lectin that is expressed on the sur-
face of all leukocytes during activation, and engagement of
CD69 maintains high expression of membrane-bound
TGFβ1 on T-cells [40]. We found that the numbers of
CD4+ and CD8+ T-cells in the lymph nodes that expressed
CD69 were around twice that of control cells. This result is
consistent with the increased numbers of CD69+ T-cells
found in the lymph nodes of mice transplanted with bone
marrow from TβRIIfx/fx x Mx1-Cre mice and with the signs
of T-cell activation in lymph nodes and spleen in those
mice [12].
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ferentiated tissue macrophages that are generally
regarded as regulatory and anti-inflammatory [41]. At
three weeks of age,Vav1-Cre x TβRIIfx/fx mice developed
spontaneous pulmonary inflammation in which few nor-
mal alveolar macrophages were found. The lack of nor-
mal alveolar macrophages could be explained by the
pro-inflammatory environment in the lung, which would
polarize peripheral blood monocytes that migrate into
the lung to an M1 phenotype and/or by re-polarization
of alveolar macrophages into proinflammatory M1
macrophages. Also, reduced production of monocytes in
the bone marrow could result in lower levels of alveolar
macrophages. However, we did not find increased levels
of IFNγ, a classic proinflammatory cytokine, in the per-
ipheral blood of the null mutant mice (Additional file 1:
Figure S4) and there was no evidence for impaired
generation of monocytes in the bone marrow of mice
lacking hematopoietic TβRII.
To examine possible macrophage-intrinsic defects, we
studied naïve, bone-marrow derived monocyte/macro-
phages for possible cell-intrinsic defects. This analysis
showed an overall decreased ability of macrophages lack-
ing TβRII signaling to produce the normal amounts of
arg1 mRNA and protein, either at basal levels or, more
markedly, when BMDMs were polarized towards an M2
phenotype with IL-4. In agreement with the regulation
of Arg-1 by TGFβ1, we found increased expression of
Arg-1 in WT macrophages stimulated with this cytokine.
Moreover, transcription of other M2 markers including
mgl2, ym1 and mcr2, but not mgl1, was also deceased in
TβRII-/- BMDMs, showing that signals through TβRII
modulate the M2 transcription program.
Ym1 is a secretory lectin that promotes Th2 cytokine
expression [42], whereas Mrc2 is a C-type receptor for
mannose that promotes remodeling of the ECM and the
uptake and degradation of collagen [29]. Both Mgl1
(clec10a) and Mgl2 as markers for alternatively activated
macrophages are type C galactose-binding lectins with a
different binding specificities to carbohydrate structures
[43]. These results show that TGFβ signaling is respon-
sible for the transcriptional upregulation of several M2-
polarization genes in macrophages that are important
for binding to carbohydrate structures present in the
ECM and on other cells and are consistent with the role
of TGFβ as a master regulator of ECM reorganization
[44,45].
We also found that macrophages lacking TβRII produce
less mRNA for lgals3, which encodes a β-galactoside-
binding lectin, and have markedly reduced Galectin-3 cell
surface expression on M1 (LPS/IFNγ-polarized) macro-
phages. Interestingly, Galectin-3 negatively regulates LPS-
induced inflammation [46]. Moreover, BMDMs lacking
lgals3 have reduced Arg-1 production and are defective inM2 polarization [32]. These results suggest that some of
the defects in TβRII-/- BMDMs could be caused by the
reduced Galectin-3 in those cells. Importantly, Akt phos-
phorylation was decreased in the IL-4-polarized M2
TβRII-/- BMDMs. This suggests that TGFβ and IL-4 co-
signal to maximally activate the Akt pathway. Although
further experiments will be needed to determine the
detailed molecular mechanisms through which TGFβ reg-
ulates M2 polarization, our findings suggest that modula-
tion of the TGFβ signaling pathway may be a method to
medically regulate macrophage polarization.
Conclusions
Taken together, our results establish a critical biological
role for TGFβ signaling in promoting the alternative ac-
tivation of macrophages. Moreover, our results suggest a
distinct contribution of monocytes/macrophages to the
systemic inflammation observed in mice with defective
TβRII function, because lack of TβRII signaling in
macrophages inhibits the polarization of macrophages to
an anti-inflammatory M2 phenotype, this could lead to
defective down-regulatory interactions with other im-
mune cells such as T-cells in the lung. These findings
further advance our knowledge of the physiological role
of TGFβ signaling and enhance our understanding of
the regulation of macrophage activation states.
Methods
Animals
The TβRIIfx/fx mice [47] on a C57BL/6 background were
obtained from the NCI Mouse Repository (Strain number:
01XN5) and were bred to Vav1-Cre mice, which were
generously provided by Dr. Dimitris Kioussis (National
Institute for Medical Research, UK) [22], to generate Vav1-
Cre x TβRIIfx/fx mice and littermate controls. TβRII-/- mice
develop a wasting syndrome 24-28 days after birth. All ani-
mal studies were approved by the Institutional Animal Care
and Use Committee (IACUC) of Children’s Hospital Los
Angeles.
Bronchoalveolar lavage
To prepare BALF, tracheas were exposed and cannulated
with an 18-gauge angiocath. Lungs were lavaged five
times with 0.8 ml of cold sterile PBS. Analysis of resi-
dent and recruited cells was performed on cells pooled
from the five washes.
Cytospin and differential staining
50-80,000 cells were spun onto glass slides at 800 rpm
for 5 min in a Shandon Cytospin II Cytocentrifuge.
Slides were stained using a Kwik-Diff stain kit (Thermo
Fisher Scientific). Cells were differentially (morphologic-
ally) counted using light microscopy.
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macrophages and peritoneal macrophages
Tissue culture reagents were from Invitrogen. LPS (cat
no. L2630) was from Sigma-Aldrich. IL-4, hTGFβ1, IL-
10 and IFNγ were purchased from PeproTech. The L929
cell line was from the American Type Culture Collec-
tion. The supernatant collected from L929 cultures that
had grown for 7 days was used to prepare L929 condi-
tioned media, as a source of M-CSF, for macrophage
maturation and expansion. Bone marrow-derived macro-
phages (BMDMs) were prepared by maturing bone mar-
row cells, which were isolated from femur and tibiae of
mice, in DMEM containing 15% FBS and 20% L929 con-
ditioned media for 11 days. BMDMs were expanded and
treated with IFNγ (10 ng/ml) and LPS (100 ng/ml) for
M1 polarization and IL-4 (10 ng/ml) for M2
polarization. BMDMs were also treated with hTGFβ1 at
5 ng/ml or dexamethasone at 40 ng/ml. Peritoneal cells
were harvested from the peritoneal cavity of mice by
lavage. Cells from 3-4 mice of the same genotype were
pooled and stained for FITC-Ly6G, PE-CD11b, PerCP-
CD45 and APC-F4/80. Peritoneal macrophages (CD45
+CD11b+Ly6G-F4/80+) were sorted out using a BD FAC-
SAria Sorter. Sorted cells were lyzed in Trizol reagent
(Invitrogen) for total RNA extraction.
Real-time RT-PCR
Total RNA was prepared using RNeasy kits (Qiagen).
cDNA was synthesized using a First Strand cDNA Syn-
thesis kit (Invitrogen). The cDNA was amplified by 40
two-step cycles (15 sec at 95°C for denaturation of the
DNA, 1 min at 60°C for primer annealing and exten-
sion). cDNA was analyzed using a SYBR green-based
quantitative fluorescence method (Applied Biosystems)
in duplicate. The PCR primers were as follows:
GAPDH: forward 5'-AGA GGG AAA TCG TGC GTG
AC-3', reverse 5'-CAA TAG TGA TGA CCT GGC
CGT-3'; ym1: forward 5'-AGA AGG GAG TTT CAA
ACC TGG G-3', reverse 5'-GTC TTG CTC ATG TGT
GTA AGT GA-3'; arginase 1: forward 5'-CTC CAA
GCC AAA GTC CTT AGA G-3', reverse 5'-AGG
AGC TGT CAT TAG GGA CAT C-3'; marc2: forward
5'-TAC AGC TCC ACG CTA TGG ATT-3', reverse 5'-
CAC TCT CCC AGT GTA GGT ACT-3'; mgl1:
forward 5'-TGA GAA AGG CTT TAA GAA CTG
GG-3', reverse 5'-GAC CAC CTG TAG TGA TGT
GGG-3'; mgl2: forward 5'-TTA GCC AAT GTG CTT
AGC TGG-3', reverse 5'-GGC CTC CAA TTC TTG
AAA CCT'-3’; lgals3: forward 5'-TTG AAG CTG ACC
ACT TCA AGG TT-3', reverse 5'- AGG TTC TTC
ATC CGA TGG TTG T-3’; TβRII: forward 5’-GGG
ATT GCC ATA GCT GTC AT-3’; reverse 5’-TGA
TGG CAC AAT TGT CAC TG-3’.Flow cytometry and quantification of different cell
populations in tissues
Data on fluorochrome-labeled monoclonal antibody-
stained cells were acquired on an Accuri cytometer
(Accuri Cytometers Inc). Data were analyzed using the
Accuri software provided by the manufacturer. FITC-
Ly6G, FITC-CD4, PE-CD8, PE-CD25, APC-CD69, APC-
CD44, PE-Gal 3, PerCP-CD45, and APC-CD11b, were
from BioLegend.
For quantification of different cell populations in tis-
sues (spleen, lymph node, thymus, bone marrow and
liver), tissues were harvested and processed for total live
cell counts using Trypan blue and a hemacytometer.
Cells were then stained with appropriate antibodies. The
percentages of cell populations were calculated using
Accuri software. The total cell number for each
leukocyte subset was calculated by multiplying total cell
counts with the percentage of that specific cell popula-
tion within the total cell population.
Efferocytosis assay
The ability of BMDM to perform phagocytosis of apop-
totic cells (efferocytosis) was tested on apoptotic primary
thymocytes isolated from 2-4-week old WT mice. After
red blood cell lysis, thymocytes were cultured overnight
in RPMI 1640 supplemented with 10% FBS, L-glutamine,
sodium pyruvate, penicillin/streptomycin and 50 μM β-
mercaptoethanol, with 6 μM CFDA. Thymocytes were
induced to undergo apoptosis by treatment of 5x106
cells/ml with 1 μM dexamethasone for 6 hrs, which was
monitored by annexin V-FITC/propidium iodide stain-
ing and FACS. BMDM were starved for 24 hr without
CSF-1 in DMEM+15% FBS; in some experiments, po-
larizing cytokines were added. After a wash with cold
DMEM, BMDM and thymocytes were preincubated at a
ratio of 1:40 on ice. Efferocytosis was initiated by
addition of prewarmed DMEM/15% FBS, followed by in-
cubation at 37°C for different times. Controls kept on
ice showed no engulfment of apoptotic thymocytes.
After co-incubation, cells were washed three times in
ice-cold PBS-/- and background fluorescence was
quenched on ice for 15 min. with 0.25 mg/ml Trypan
blue in 0.02 M ammonium acetate, 150 mM NaCl, pH
4.0. Cells were washed 3 times, fixed and stained with
TRITC-phalloidin. Phagocytosis was evaluated by count-
ing 200–300 macrophages per slide from triplicate
experiments. Results for the phagocytosis index are
expressed as the percentage of macrophages that had
engulfed one or more thymocyte.
Western blots
Cell lysates were resolved by SDS-PAGE and immuno-
blotted with anti-Arginase-1 (BD Bioscience), anti-
phospho-Stat6 (Tyr641, Millipore), anti-phospho-Akt
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Signaling). Blots were stripped and re-blotted with
anti–β-actin (Sigma), anti-GAPDH (Millipore), anti-
Stat6 or anti-Akt (Cell Signaling) antibodies. Band inten-
sities were analyzed using Un-Scan-It software (Silk Sci-
entific, Orem, UT) on the scanned images of the blots.ELISA
Blood was collected from WT and TβRII-/- mice at post-
natal day 18-21. After clotting of blood, serum was har-
vested by centrifugation at 800 g for 10 min. Serum
IFNγ levels were measured using a mouse IFNγ ELISA
kit (Biolegend) according to the manufacturer’s protocol.Statistical analysis
Data are expressed as mean ± SEM and analyzed by the
unpaired Student's t test using Prism (GraphPad) soft-
ware, unless indicated otherwise in the figure legend.
p< 0.05 was considered to be statistically significant.Additional file
Additional file 1: Figure S1. Analysis of T-cells in thymus, spleen and
lymph nodes of WT and TβRII-/- mice. (A) FACS of WT and TβRII-/- thymus
for CD4- and CD8-positive cells. (B) Cell counts of double negative (DN),
double positive (DP), CD4 single positive and CD8 single positive cells in
thymus. (C) Percentage of CD4 + CD25+ T-cells in thymus, lymph node
and spleen of WT and TβRII-/- mice. Solid bar, WT; Open bar, TβRII-/- mice.
(D) Left, single-cell suspensions of lymph nodes were gated for
lymphocytes (P1) and right, CD4+ and CD8+ T cells. (E) Representative
histogram of CD44 expression on CD4+ T cells of TβRII-/- (red line) and
control (black line) mice. (F) Percentage of CD44+ cells in spleen and
lymph nodes using the strategy in (D). (G) Percentage of CD69+ cells in
lymph nodes. **, p< 0.05; ***p< 0.005. Figure S2 BMDMs with or without
TβRII function. (A) Gating strategy for FACS on BMDMs of the indicated
genotypes using CD11b and Ly6G. Right panel, the expression of F4/80, a
pan-macrophage surface marker. (B) BMDMs were treated with the
stimuli as indicated to the right for 24 hrs. Representative phase contrast
images are shown. (C) Percentage BMDMs that had engulfed at least one
apoptotic thymocyte (efferocytosis) in standard medium. (D) Efferocytosis
of BMDMs with or without TβRII function treated for 24 hrs with medium
alone (M0); 100 ng/ml LPS and 10 ng/ml IFNγ (M1), 10 ng/ml IL-4 (M2a),
or 5 ng/ml hTGFβ1. M0 compared to M1, **p = 0.003. (E) Genomic DNA
was extracted from WT and TβRII-/- BMDMs (n = 4). Real-time PCR was
used to quantify the levels of TβRII. The level of TβRII in one WT sample
was set to 1 and the levels of TβRII in other samples were normalized to
that of the chosen WT sample. Figure S3 Expression of iNOS and Arg1 in
WT and smad3-/- BMDMs. Western blot analysis of Arg1 and iNOS in
BMDMs of WT and smad3-/- mice. Figure S4 IFNγ levels in the blood of
WT and TβRII-/- mice. ELISA was used to measure IFNγ levels in the
serum of WT and TβRII-/- mice on postnatal day 18-21 (n = 4).Abbreviations
BAL: Bronchoalveolar lavage; BALF: Bronchoalveolar lavage fluid;
BMDMs: Bone marrow-derived macrophages; ECM: Extracellular matrix;
TGFβ: Transforming growth factor beta; TβRII: TGFβ type II receptor.
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